Bendamustine: Phase II start

In March, SymBio will begin an open-label, Japanese Phase II trial evaluating 100 mg/m 2/day bendamustine for 2 consecutive days of a 4-week cycle in 10 patients. Astellas granted rights to Treanda bendamustine to Cephalon Corp., which Teva acquired, in North America, to Mundipharma in Europe and to SymBio in Japan, China, Korea, Taiwan and Singapore. Cephalon granted exclusive rights to bendamustine in Canada to H. Lundbeck, while SymBio granted exclusive rights to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax. ...